Lassa Fever
What is Lassa fever?
Lassa fever is an acute viral illness that
occurs in West Africa. The illness was
discovered in 1969 when two missionary nurses
died in Nigeria, West Africa. The cause of the
illness was found to be Lassa virus, named after
the town in Nigeria where the first cases
originated. The virus, a member of the virus
family Arenaviridae, is a single-stranded RNA
virus and is zoonotic, or animal-borne.
In areas of Africa where the disease is endemic
(that is, constantly present), Lassa fever is a
significant cause of morbidity and mortality.
While Lassa fever is mild or has no observable
symptoms in about 80% of people infected with
the virus, the remaining 20% have a severe
multisystem disease. Lassa fever is also
associated with occasional epidemics, during
which the case-fatality rate can reach 50%.
Where is Lassa fever found?
Lassa fever is an endemic disease in portions of
West Africa. It is recognized in Guinea,
Liberia, Sierra Leone, as well as Nigeria.
However, because the rodent species which carry
the virus are found throughout West Africa, the
actual geographic range of the disease may
extend to other countries in the region.
In what animal host is Lassa virus maintained?
The reservoir, or host, of Lassa virus is a
rodent known as the "multimammate rat" of the
genus Mastomys. It is not certain which species
of Mastomys are associated with Lassa; however,
at least two species carry the virus in Sierra
Leone. Mastomys rodents breed very frequently,
produce large numbers of offspring, and are
numerous in the savannas and forests of West,
Central, and East Africa. In addition, Mastomys
generally readily colonize human homes. All
these factors together contribute to the
relatively efficient spread of Lassa virus from
infected rodents to humans.
How do humans get Lassa fever?
There are a number of ways in which the virus
may be transmitted, or spread, to humans. The
Mastomys rodents shed the virus in urine and
droppings. Therefore, the virus can be
transmitted through direct contact with these
materials, through touching objects or eating
food contaminated with these materials, or
through cuts or sores. Because Mastomys rodents
often live in and around homes and scavenge on
human food remains or poorly stored food,
transmission of this sort is common. Contact
with the virus also may occur when a person
inhales tiny particles in the air contaminated
with rodent excretions. This is called aerosol
or airborne transmission. Finally, because
Mastomys rodents are sometimes consumed as a
food source, infection may occur via direct
contact when they are caught and prepared for
food.
Lassa fever may also spread through
person-to-person contact. This type of
transmission occurs when a person comes into
contact with virus in the blood, tissue,
secretions, or excretions of an individual
infected with the Lassa virus. The virus cannot
be spread through casual contact (including
skin-to-skin contact without exchange of body
fluids). Person-to-person transmission is common
in both village and health care settings, where,
along with the above-mentioned modes of
transmission, the virus also may be spread in
contaminated medical equipment, such as reused
needles (this is called nosocomial
transmission).
What are the symptoms of Lassa fever?
Signs and symptoms of Lassa fever typically
occur 1-3 weeks after the patient comes into
contact with the virus. These include fever,
retrosternal pain (pain behind the chest wall),
sore throat, back pain, cough, abdominal pain,
vomiting, diarrhea, conjunctivitis, facial
swelling, proteinuria (protein in the urine),
and mucosal bleeding. Neurological problems have
also been described, including hearing loss,
tremors, and encephalitis. Because the symptoms
of Lassa fever are so varied and nonspecific,
clinical diagnosis is often difficult.
How is the disease diagnosed in the laboratory?
Lassa fever is
most often diagnosed by using enzyme-linked
immunosorbent serologic assays (ELISA), which
detect IgM and IgG antibodies as well as Lassa
antigen. The virus itself may be cultured in 7
to 10 days. Immunohistochemistry performed on
tissue specimens can be used to make a
post-mortem diagnosis. The virus can also be
detected by reverse transcription-polymerase
chain reaction (RT-PCR); however, this method is
primarily a research tool.
Are there complications after recovery?
The most common complication of Lassa fever is
deafness. Various degrees of deafness occur in
approximately one-third of cases, and in many
cases hearing loss is permanent. As far as is
known, severity of the disease does not affect
this complication: deafness may develop in mild
as well as in severe cases. Spontaneous
abortion is another serious complication.
What proportion of people die from the illness?
Approximately 15%-20% of patients hospitalized
for Lassa fever die from the illness. However,
overall only about 1% of infections with Lassa
virus result in death. The death rates are
particularly high for women in the third
trimester of pregnancy, and for fetuses, about
95% of which die in the uterus of infected
pregnant mothers.
How is Lassa fever treated?
Ribavirin, an antiviral drug, has been used with
success in Lassa fever patients. It has been
shown to be most effective when given early in
the course of the illness. Patients should also
receive supportive care consisting of
maintenance of appropriate fluid and electrolyte
balance, oxygenation and blood pressure, as well
as treatment of any other complicating
infections.
What groups are at risk for getting the illness?
Individuals at risk are those who live or visit
areas with a high population of Mastomys rodents
infected with Lassa virus or are exposed to
infected humans. Hospital staff are not at great
risk for infection as long as protective
measures are taken.
How is Lassa fever prevented?
Primary transmission of the Lassa virus from its
host to humans can be prevented by avoiding
contact with Mastomys rodents, especially in the
geographic regions where outbreaks occur.
Putting food away in rodent-proof containers and
keeping the home clean help to discourage
rodents from entering homes. Using these rodents
as a food source is not recommended. Trapping in
and around homes can help reduce rodent
populations. However, the wide distribution of
Mastomys in Africa makes complete control of
this rodent reservoir impractical.
When caring for patients with Lassa fever,
further transmission of the disease through
person-to-person contact or nosocomial routes
can be avoided by taking preventive precautions
against contact with patient secretions
(together called VHF isolation precautions or
barrier nursing methods). Such precautions
include wearing protective clothing, such as
masks, gloves, gowns, and goggles; using
infection control measures, such as complete
equipment sterilization; and isolating infected
patients from contact with unprotected persons
until the disease has run its course.
What
needs to be done to address the threat of Lassa
fever?
Further educating people in high-risk areas
about ways to decrease rodent populations in
their homes will aid in the control and
prevention of Lassa fever. Other challenges
include developing more rapid diagnostic tests
and increasing the availability of the only
known drug treatment, ribavirin. Research is
presently under way to develop a vaccine for
Lassa fever.